ADVERTISEMENT
References
- Wang K, Wei G, Liu D. CD19: a biomarker for B cell development, lymphoma diagnosis and therapy. Exp Hematol Oncol. 2012;1(1):36.
- Kochenderfer JN, Rosenberg SA. Treating B-cell cancer with T cells expressing anti-CD19 chimeric antigen receptors. Nat Rev Clin Oncol. 2013;10(5):267‐276.
- Yam-Puc JC, Zhang L, Zhang Y, Toellner KM. Role of B-cell receptors for B-cell development and antigen-induced differentiation. F1000Res. 2018;7:429.
- Scheuermann RH, Racila E. CD19 antigen in leukemia and lymphoma diagnosis and immunotherapy. Leuk Lymphoma. 1995;18(5-6):385‐397.
- Francis J, Dharmadhikari AV, Sait SN, et al. CD19 expression in acute leukemia is not restricted to the cytogenetically aberrant populations. Leuk Lymphoma. 2013;54(7):1517‐1520.
- Liu D, Shimonov J, Primanneni S, et al. t(8;14;18): a 3-way chromosome translocation in two patients with Burkitt's lymphoma/leukemia. Mol Cancer. 2007;6:35.
- Awan FT, Lapalombella R, Trotta R, et al. CD19 targeting of chronic lymphocytic leukemia with a novel Fc-domain-engineered monoclonal antibody. Blood. 2010;115(6):1204‐1213.
- Kimura M, Yamaguchi M, Ueno S, et al. CD19-negative diffuse large B-cell lymphoma shows high serum LDH level and poor prognosis. Blood. 2005;106(11):1924.
- Yang W, Agrawal N, Patel J, et al. Diminished expression of CD19 in B-cell lymphomas. Cytometry B Clin Cytom. 2005;63(1):28‐35.
- Rastogi P, Sreedharanunni S, Yanamandra U, et al. Morphologic confounders and CD19 negativity in a case of hairy cell leukemia. Mediterr J Hematol Infect Dis. 2017;9(1):e2017033.
- Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD19 and CD20 in chronic B cell leukaemias. J Clin Pathol. 1998;51(5):364‐369.
- Onea AS, Jazirehi AR. CD19 chimeric antigen receptor (CD19 CAR)-redirected adoptive T-cell immunotherapy for the treatment of relapsed or refractory B-cell Non-Hodgkin's Lymphomas. Am J Cancer Res. 2016;6(2):403‐424.
